ACR acrux limited

6.25%

1.7¢

Ann: Acrux and Harris terminate license agreement, page-14

First 14 Last

Share
Profile

Follow
Slogger

7,730 Posts.

770

18/10/21

13:48

Post #: 56878620
Share

Originally posted by mwilson25: ↑

After the whole Axiron caper blew up on them, it took a while before they were able to get going on a new direction with these generic drugs. I knew at the time that they were being too hopeful with the timeline for approvals but I thought to myself that if I wait out the drug development time the sp will recover. I was of the view that the biggest hurdle was the approvals with the FDA (as it was out of our control)

I never thought the following:-

1. Very low royalties from Evamist/Lenzetto after 1 decade on the market (yes 1 decade) . I had assumed this would grow steadily during the product development.

2. Commercialization of approved products now dragging very badly.

3. They would partner with bankrupts.

5. Economics of the approved products looking dodgy (surely they must have thought about this before beginning work on them??).

4. Cash burn still enormous.

The company is now in a world of pain.

They took twice as long as they should have to get the approvals. Now they appear to be taking twice as long as they should to commercialize also (maybe commercial partners are down grading priority if the products are low value??).

Now I am the fool that invested with them - no question.

But is it not reasonable for me to expect some kind of performance (even an average performance) in getting these products generating revenue?

I am pissed off.

Expand

IMO only real way of getting things going is to change the management structure - starting from the top as IMO that has been an issue for quite some time.
they should IMO also show some respect to SH's and cease the paying of bonuses given the lackk of generated profits and more importantly the destruction of SH wealth!
a new beginning starts from change at the top!!
all IMO.

ACR Price at posting: 12.0¢ Sentiment: None Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 14 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.7¢		Change 0.001(6.25%)		Mkt cap ! $6.931M

Open	High	Low	Value	Volume
1.6¢	1.7¢	1.6¢	$6.279K	376.7K

Buyers (Bids)

No.	Vol.	Price($)
3	741559	1.6¢

Sellers (Offers)

Price($)	Vol.	No.
1.7¢	193057	2

View Market Depth

No.	Vol.	Price($)
3	741559	0.016
6	1259314	0.015
3	420000	0.014
2	397000	0.013
1	80000	0.012

Price($)	Vol.	No.
0.017	193057	2
0.018	252359	2
0.019	677115	3
0.020	50000	1
0.021	203466	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

ACR (ASX) Chart

Ann: Acrux and Harris terminate license agreement, page-14

'Not possible' to port renewable gas: ACCC takes AGN to court

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

Boss extends June win streak with boosted Alta Mesa extraction rates

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Acrux and Harris terminate license agreement, page-14

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

Boss extends June win streak with boosted Alta Mesa extraction rates

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News